London-listed AstraZeneca (LSE: AZN) has received a positive reimbursement decision from the UK’s health technology assessor, for the immuno-oncology product Imfinzi (durvalumab).
The decision means the therapy is now available as an option for people with stage 3 unresectable non-small cell lung cancer (NSCLC), via a dedicated fund for oncology treatments, the Cancer Drugs Fund (CDF).
Funding through the CDF is subject to eligibility criteria being met. The therapy is not routinely funded through the country’s national healthcare provider for this indication.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze